SG11201408619WA - Saxagliptin salts - Google Patents
Saxagliptin saltsInfo
- Publication number
- SG11201408619WA SG11201408619WA SG11201408619WA SG11201408619WA SG11201408619WA SG 11201408619W A SG11201408619W A SG 11201408619WA SG 11201408619W A SG11201408619W A SG 11201408619WA SG 11201408619W A SG11201408619W A SG 11201408619WA SG 11201408619W A SG11201408619W A SG 11201408619WA
- Authority
- SG
- Singapore
- Prior art keywords
- saxagliptin
- international
- delhi
- singh
- del
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2061DE2012 | 2012-07-02 | ||
IN3917DE2012 | 2012-12-19 | ||
PCT/IB2013/055429 WO2014006569A2 (fr) | 2012-07-02 | 2013-07-02 | Sels de saxagliptine |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408619WA true SG11201408619WA (en) | 2015-01-29 |
Family
ID=54193750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408619WA SG11201408619WA (en) | 2012-07-02 | 2013-07-02 | Saxagliptin salts |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2867206A2 (fr) |
AU (1) | AU2013285078A1 (fr) |
CA (1) | CA2879824A1 (fr) |
SG (1) | SG11201408619WA (fr) |
WO (1) | WO2014006569A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9994523B2 (en) | 2012-05-24 | 2018-06-12 | Apotex Inc. | Salts of Saxagliptin with organic acids |
WO2015166466A1 (fr) * | 2014-05-01 | 2015-11-05 | Sun Pharmaceutical Industries Limited | Forme cristalline d'acétate de saxagliptine |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
US7420079B2 (en) | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
TW200538122A (en) | 2004-03-31 | 2005-12-01 | Bristol Myers Squibb Co | Process for preparing a dipeptidyl peptidase Ⅳ inhibitor and intermediates employed therein |
US7741082B2 (en) | 2004-04-14 | 2010-06-22 | Bristol-Myers Squibb Company | Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor |
US7214702B2 (en) | 2004-05-25 | 2007-05-08 | Bristol-Myers Squibb Company | Process for producing a dipeptidyl peptidase IV inhibitor |
PE20090696A1 (es) * | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
CN102459170B (zh) | 2009-04-09 | 2014-07-23 | 桑多斯股份公司 | 沙格列汀的结晶形式 |
EP2601175A1 (fr) | 2010-08-06 | 2013-06-12 | Sandoz AG | Nouveau composé cristallin comprenant de la saxagliptine et de l'acide phosphorique |
WO2012017029A1 (fr) * | 2010-08-06 | 2012-02-09 | Sandoz Ag | Nouveaux sels de saxagliptine comportant des diacides organiques |
WO2012047871A1 (fr) | 2010-10-04 | 2012-04-12 | Assia Chemical Industries Ltd | Polymorphes de chlorhydrate de saxagliptine et leurs procédés de préparation |
CN102086172A (zh) * | 2011-01-13 | 2011-06-08 | 廖国超 | 沙格列汀的药用盐及其制备方法 |
-
2013
- 2013-07-02 WO PCT/IB2013/055429 patent/WO2014006569A2/fr active Application Filing
- 2013-07-02 SG SG11201408619WA patent/SG11201408619WA/en unknown
- 2013-07-02 CA CA2879824A patent/CA2879824A1/fr not_active Abandoned
- 2013-07-02 EP EP13762566.1A patent/EP2867206A2/fr not_active Withdrawn
- 2013-07-02 AU AU2013285078A patent/AU2013285078A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2014006569A3 (fr) | 2014-03-06 |
WO2014006569A2 (fr) | 2014-01-09 |
CA2879824A1 (fr) | 2014-01-09 |
AU2013285078A1 (en) | 2015-01-29 |
EP2867206A2 (fr) | 2015-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201408261UA (en) | Syringe | |
SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
SG11201408739VA (en) | Inhibitors of hepatitis c virus | |
SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
SG11201408094YA (en) | Neprilysin inhibitors | |
SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
SG11201804811WA (en) | Fenfluramine compositions and methods of preparing the same | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
SG11201900545TA (en) | Pharmaceutical compounds | |
SG11201407988UA (en) | Process for improved opioid synthesis | |
SG11201407934UA (en) | Camsylate salt | |
SG11201407184PA (en) | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals | |
SG11201407337QA (en) | Cyclodextrin complexation methods for formulating peptide proteasome inhibitors | |
SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
SG11201407319YA (en) | Compositions and methods for treatment of inflammatory bowel disease | |
SG11201408685WA (en) | Antibacterial microelement chelates and the use thereof in animal feeds |